Updated:
Leica Biosystems
Leica Biosystems, a Danaher company and a global leader in anatomic pathology, provides integrated workflow solutions from biopsy to AI diagnostics since 1872.
Leica Biosystems
Leica Biosystems is a global leader in workflow solutions and automation, integrating each step in the workflow from biopsy to diagnosis.
General information
Firm type
Asset Manager
Year founded
1872
Location
Region
North America
Country
United States
City
Nussloch, Germany
Corporate office
St. Louis, MO, United States
Principals
Koichi Ohshima
Professor, Department of Pathology, Kurume University
Sylvia L. Asa
Consultant in Endocrine Pathology, University Hospitals Cleveland Medical Center
Sector focus
Frequently asked questions
What is the commercial relationship between Leica Biosystems and Danaher?
Leica Biosystems operates as a Danaher operating company. Since being acquired by Danaher (now part of a larger science and technology conglomerate), Leica Biosystems benefits from Danaher's capital, R&D infrastructure, and regulatory expertise, which allows it to scale its pathology workflow solutions globally.
What investment stages and asset classes does Leica Biosystems target?
Leica Biosystems does not act as an external investor; it is a Danaher operating company that develops, manufactures, and sells anatomic pathology products and diagnostics. Its focus is on developing instruments, consumables, software, and AI tools for cancer diagnostics.
How does Leica Biosystems source and develop its AI pathology tools?
Leica Biosystems develops some AI tools internally and partners with third-party developers through its Aperio AI Store. In 2026, the firm signed a global reseller agreement with Mindpeak to expand access to AI pathology solutions. The firm also collaborates with pharmaceutical companies like AstraZeneca and Daiichi Sankyo to develop AI-powered companion diagnostics.
What is the geographic footprint of Leica Biosystems?
The firm has a global presence with over 3,000 experts worldwide. Headquarters are in St. Louis, USA, with significant operations in Europe (Newcastle, UK) and Asia. Reference customers include institutions in Japan (Kurume University) and the United States (University Hospitals Cleveland Medical Center).
Does Leica Biosystems participate in external fund commitments or direct investments?
No. Leica Biosystems is a Danaher operating company focused on developing and selling pathology equipment, consumables, and digital solutions. It does not function as an investment entity or asset manager.
How is Leica Biosystems related to the Mindpeak reseller agreement announced in 2026?
Leica Biosystems and Mindpeak entered a global reseller agreement in 2026, allowing Leica to distribute Mindpeak's AI pathology software through its Aperio AI Store platform. This expands the AI tools available to Leica's customers within a single interface.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: